Radius Health (RDUS) Misses Q1 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Radius Health, Inc. First Quarter 2022 Results
May 5, 2022 7:30 AM EDTQ1 2022 TYMLOS® product net revenue of $43 million vs. $45 million in Q1 2021
° Q1 results: in-line with previously guided 1H 2022 company target of $97 million
° Reiterating FY 2022 TYMLOS Net Revenue guidance of $232 million
° Seasonality, as previously announced: 42% of net revenue in 1H and 58% in 2H 2022
° Patient Growth: average active patients on therapy increased by 4% compared to Q1 2021Productivity improvement continued: revenue per commercial headcount up 32% vs. Q1 2021TYMLOS for the Male indication: sNDA filed in Q1 2022 with launch planned for early Q1 2023Additional patent granted by USPTO for TYMLOS: extending exclusivity to January 10,... More
